This is an open-label, multicenter, Phase 2 study designed to evaluate the efficacy and safety of AHB-137 injection in participants with chronic hepatitis B (CHB) with low hepatitis B surface antigen (HBsAg) levels.
Voluntarily participate in the study and sign the informed consent form;
18-65 years of age (including boundary values) ;
Body mass index met the requirements;
Participants with CHB who are HBsAg or HBV DNA positive for at least 6 months;
Uncontrolled and stable clinically significant abnormalities other than a history of CHB infection;
Associated liver disease;
Any serious infection other than CHB infection requires intravenous anti-infective therapy;
HCV RNA positive, HIV antibody positive, syphilis positive;